 Tara Hendry-Hofer
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antidotes | 17 | 2026 | 145 | 5.020 |
Why?
| | Cyanides | 12 | 2026 | 58 | 2.550 |
Why?
| | Sulfides | 5 | 2025 | 92 | 2.090 |
Why?
| | Potassium Cyanide | 6 | 2026 | 24 | 1.960 |
Why?
| | Swine | 19 | 2026 | 822 | 1.630 |
Why?
| | Cobamides | 4 | 2022 | 25 | 1.450 |
Why?
| | Hydrogen Sulfide | 4 | 2022 | 47 | 1.060 |
Why?
| | Mustard Gas | 11 | 2018 | 77 | 1.040 |
Why?
| | Injections, Intramuscular | 7 | 2024 | 146 | 0.860 |
Why?
| | Disease Models, Animal | 13 | 2026 | 4552 | 0.820 |
Why?
| | Chemical Warfare Agents | 10 | 2018 | 89 | 0.790 |
Why?
| | Tetrathionic Acid | 2 | 2021 | 4 | 0.770 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 64 | 0.750 |
Why?
| | Tranexamic Acid | 1 | 2023 | 59 | 0.740 |
Why?
| | Fibrinolysis | 2 | 2023 | 164 | 0.730 |
Why?
| | Poisoning | 2 | 2023 | 119 | 0.700 |
Why?
| | Sulfhydryl Compounds | 3 | 2022 | 189 | 0.640 |
Why?
| | Thiadiazoles | 1 | 2020 | 25 | 0.620 |
Why?
| | Hemorrhage | 1 | 2023 | 822 | 0.540 |
Why?
| | Inhalation Exposure | 9 | 2020 | 103 | 0.500 |
Why?
| | Animals | 35 | 2026 | 37952 | 0.460 |
Why?
| | Airway Obstruction | 5 | 2014 | 153 | 0.410 |
Why?
| | Thiosulfates | 3 | 2021 | 19 | 0.360 |
Why?
| | Thiocyanates | 3 | 2024 | 28 | 0.280 |
Why?
| | Lung | 6 | 2026 | 4101 | 0.260 |
Why?
| | Fibrinolytic Agents | 3 | 2014 | 297 | 0.250 |
Why?
| | Platinum | 1 | 2026 | 48 | 0.230 |
Why?
| | Respiratory Insufficiency | 3 | 2014 | 326 | 0.230 |
Why?
| | Glyoxylates | 2 | 2023 | 8 | 0.230 |
Why?
| | Methionine | 1 | 2026 | 161 | 0.230 |
Why?
| | Administration, Intranasal | 1 | 2025 | 94 | 0.220 |
Why?
| | Metalloporphyrins | 3 | 2016 | 63 | 0.220 |
Why?
| | Fentanyl | 1 | 2026 | 128 | 0.210 |
Why?
| | Administration, Oral | 4 | 2021 | 862 | 0.210 |
Why?
| | Rats, Sprague-Dawley | 12 | 2018 | 2524 | 0.210 |
Why?
| | Tandem Mass Spectrometry | 2 | 2023 | 571 | 0.190 |
Why?
| | Antioxidants | 4 | 2016 | 550 | 0.190 |
Why?
| | Random Allocation | 2 | 2020 | 365 | 0.190 |
Why?
| | Cerebral Cortex | 1 | 2026 | 471 | 0.180 |
Why?
| | Thromboplastin | 2 | 2012 | 67 | 0.180 |
Why?
| | Tissue Plasminogen Activator | 2 | 2014 | 248 | 0.170 |
Why?
| | Epithelial Cells | 3 | 2014 | 1127 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 198 | 0.170 |
Why?
| | Bronchi | 3 | 2012 | 263 | 0.170 |
Why?
| | Soil Pollutants | 1 | 2020 | 16 | 0.170 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 124 | 0.160 |
Why?
| | Respiratory Mucosa | 2 | 2014 | 322 | 0.160 |
Why?
| | Memory | 1 | 2023 | 294 | 0.160 |
Why?
| | Disulfides | 1 | 2020 | 94 | 0.160 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2023 | 196 | 0.160 |
Why?
| | Apoptosis | 3 | 2026 | 2434 | 0.150 |
Why?
| | Chemically-Induced Disorders | 1 | 2019 | 2 | 0.150 |
Why?
| | Toxicokinetics | 1 | 2018 | 8 | 0.140 |
Why?
| | Toxicity Tests, Acute | 1 | 2018 | 8 | 0.140 |
Why?
| | Terrorism | 1 | 2018 | 27 | 0.140 |
Why?
| | Mass Casualty Incidents | 1 | 2018 | 50 | 0.140 |
Why?
| | Bronchiolitis Obliterans | 1 | 2018 | 61 | 0.140 |
Why?
| | Glycine | 1 | 2019 | 186 | 0.130 |
Why?
| | Chlorine | 2 | 2015 | 59 | 0.130 |
Why?
| | Arterioles | 1 | 2017 | 52 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2018 | 638 | 0.130 |
Why?
| | Zebrafish | 1 | 2022 | 532 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2026 | 1145 | 0.130 |
Why?
| | Rats | 9 | 2021 | 5582 | 0.130 |
Why?
| | Female | 9 | 2026 | 78636 | 0.120 |
Why?
| | Male | 14 | 2025 | 72664 | 0.120 |
Why?
| | Cognition | 1 | 2025 | 1262 | 0.120 |
Why?
| | Administration, Inhalation | 5 | 2018 | 571 | 0.120 |
Why?
| | Risk | 1 | 2018 | 916 | 0.120 |
Why?
| | Factor VII | 2 | 2012 | 24 | 0.120 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 32 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2019 | 577 | 0.110 |
Why?
| | Models, Animal | 3 | 2024 | 393 | 0.100 |
Why?
| | Pulmonary Fibrosis | 1 | 2018 | 395 | 0.100 |
Why?
| | Bronchitis | 1 | 2014 | 29 | 0.100 |
Why?
| | Toxicity Tests | 1 | 2014 | 53 | 0.100 |
Why?
| | Oxidative Stress | 3 | 2016 | 1351 | 0.100 |
Why?
| | Thrombosis | 1 | 2017 | 401 | 0.100 |
Why?
| | Thrombolytic Therapy | 1 | 2014 | 164 | 0.100 |
Why?
| | Lung Injury | 1 | 2016 | 241 | 0.100 |
Why?
| | Receptor, PAR-2 | 1 | 2012 | 6 | 0.090 |
Why?
| | Receptor, PAR-1 | 1 | 2012 | 17 | 0.090 |
Why?
| | Myocytes, Cardiac | 2 | 2015 | 544 | 0.090 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 611 | 0.090 |
Why?
| | Biomarkers | 1 | 2024 | 4282 | 0.090 |
Why?
| | Heparin | 1 | 2014 | 246 | 0.090 |
Why?
| | Lipoproteins | 1 | 2013 | 166 | 0.090 |
Why?
| | Fibrin | 4 | 2013 | 84 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 341 | 0.090 |
Why?
| | Reactive Nitrogen Species | 1 | 2011 | 16 | 0.090 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 372 | 0.090 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 266 | 0.080 |
Why?
| | Olfactory Mucosa | 1 | 2011 | 39 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 296 | 0.080 |
Why?
| | Nasal Cavity | 1 | 2011 | 61 | 0.080 |
Why?
| | Pneumonia | 1 | 2016 | 635 | 0.080 |
Why?
| | Humans | 13 | 2023 | 145140 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2021 | 11741 | 0.080 |
Why?
| | Time Factors | 5 | 2019 | 7107 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1126 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 955 | 0.060 |
Why?
| | Myocardium | 2 | 2026 | 931 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 968 | 0.060 |
Why?
| | Necrosis | 1 | 2026 | 243 | 0.050 |
Why?
| | Blotting, Western | 3 | 2013 | 1177 | 0.050 |
Why?
| | Sus scrofa | 1 | 2024 | 63 | 0.050 |
Why?
| | Forensic Toxicology | 1 | 2024 | 3 | 0.050 |
Why?
| | Mice | 4 | 2026 | 18303 | 0.050 |
Why?
| | Thiazoles | 1 | 2024 | 140 | 0.050 |
Why?
| | Limit of Detection | 1 | 2023 | 92 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 2026 | 0.050 |
Why?
| | Hydrogen Cyanide | 1 | 2022 | 5 | 0.050 |
Why?
| | Specimen Handling | 1 | 2024 | 182 | 0.050 |
Why?
| | Granuloma, Respiratory Tract | 1 | 2002 | 13 | 0.050 |
Why?
| | Microdissection | 2 | 2013 | 13 | 0.040 |
Why?
| | Gene Knockdown Techniques | 2 | 2013 | 333 | 0.040 |
Why?
| | Pyruvic Acid | 1 | 2022 | 51 | 0.040 |
Why?
| | Patch Tests | 1 | 2002 | 60 | 0.040 |
Why?
| | Cricetulus | 1 | 2021 | 118 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2023 | 591 | 0.040 |
Why?
| | Trachea | 2 | 2014 | 258 | 0.040 |
Why?
| | CHO Cells | 1 | 2021 | 169 | 0.040 |
Why?
| | Fumigation | 1 | 2020 | 3 | 0.040 |
Why?
| | Temperature | 1 | 2024 | 632 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 302 | 0.040 |
Why?
| | Beryllium | 1 | 2002 | 161 | 0.040 |
Why?
| | Immunoglobulin M | 2 | 2013 | 265 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2013 | 634 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 450 | 0.040 |
Why?
| | Pesticides | 1 | 2020 | 59 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 284 | 0.040 |
Why?
| | Pilot Projects | 1 | 2026 | 1889 | 0.040 |
Why?
| | Rabbits | 1 | 2021 | 652 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 417 | 0.040 |
Why?
| | MicroRNAs | 1 | 2026 | 686 | 0.040 |
Why?
| | Poisons | 1 | 2019 | 20 | 0.040 |
Why?
| | Oxygen | 2 | 2014 | 978 | 0.040 |
Why?
| | Phosphorylation | 1 | 2023 | 1706 | 0.040 |
Why?
| | Apnea | 1 | 2018 | 26 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2018 | 85 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1131 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2018 | 85 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 171 | 0.030 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 53 | 0.030 |
Why?
| | Hemodynamics | 1 | 2023 | 1115 | 0.030 |
Why?
| | Hypotension | 1 | 2018 | 127 | 0.030 |
Why?
| | Hippocampus | 1 | 2023 | 969 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2018 | 176 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2017 | 92 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 99 | 0.030 |
Why?
| | Peptides | 1 | 2023 | 997 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 288 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 146 | 0.030 |
Why?
| | Proteins | 2 | 2013 | 1022 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 543 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2015 | 4142 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1043 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 5 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 23 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1371 | 0.030 |
Why?
| | Cell Proliferation | 2 | 2013 | 2504 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 94 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2014 | 42 | 0.030 |
Why?
| | Mitochondria, Heart | 1 | 2015 | 105 | 0.030 |
Why?
| | Pulmonary Ventilation | 1 | 2014 | 82 | 0.030 |
Why?
| | Cell Movement | 2 | 2013 | 959 | 0.030 |
Why?
| | Blood Coagulation Tests | 1 | 2014 | 72 | 0.030 |
Why?
| | Respiration | 1 | 2014 | 206 | 0.030 |
Why?
| | Electric Impedance | 1 | 2014 | 108 | 0.030 |
Why?
| | Neurons | 1 | 2023 | 1644 | 0.030 |
Why?
| | Acidosis | 1 | 2014 | 105 | 0.020 |
Why?
| | Prothrombin | 1 | 2013 | 25 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2016 | 506 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2013 | 106 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2015 | 244 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 781 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 499 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 247 | 0.020 |
Why?
| | Weight Loss | 1 | 2018 | 845 | 0.020 |
Why?
| | Fibrinogen | 1 | 2013 | 180 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 8035 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 192 | 0.020 |
Why?
| | Milk Proteins | 1 | 2011 | 33 | 0.020 |
Why?
| | Factor Xa | 1 | 2011 | 36 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 138 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2011 | 155 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2013 | 372 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 451 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 847 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 200 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2011 | 162 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 382 | 0.020 |
Why?
| | Lung Diseases | 1 | 2017 | 780 | 0.020 |
Why?
| | Blood Coagulation | 1 | 2012 | 274 | 0.020 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2010 | 112 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1368 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 132 | 0.020 |
Why?
| | Wound Healing | 1 | 2012 | 354 | 0.020 |
Why?
| | Peroxidase | 1 | 2010 | 168 | 0.020 |
Why?
| | Cell Survival | 1 | 2012 | 1100 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 318 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1713 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 2048 | 0.020 |
Why?
| | Erythrocytes | 1 | 2014 | 747 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2588 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 23 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 185 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 333 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5208 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2876 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2127 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2881 | 0.010 |
Why?
| | Skin | 1 | 2002 | 753 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2002 | 1138 | 0.010 |
Why?
|
|
Hendry-Hofer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|